Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes
Mette Julsgaard, Christian L Hvas, Richard B Gearry, Peter R Gibson, Jan Fallingborg, Miles P Sparrow, Bo M Bibby, William R Connell, Steven J Brown, Michael A Kamm, Ian C Lawrance, Thea Vestergaard, Lise Svenningsen, Mille Baekdal, Heidi Kammerlander, Alissa Walsh, Trine Boysen, Peter Bampton, Graham Radford-Smith, Jens Kjeldsen Show all
INFLAMMATORY BOWEL DISEASES | OXFORD UNIV PRESS INC | Published : 2020
BACKGROUND: Active inflammatory bowel disease (IBD) adversely affects pregnancy outcomes. Little is known about the risk of relapse after stopping anti-tumor necrosis factor (anti-TNF) treatment during pregnancy. We assessed the risk of relapse before delivery in women who discontinued anti-TNF treatment before gestational week (GW) 30, predictors of reduced infant birth weight, a marker associated with long-term adverse outcomes, and rates and satisfaction with counseling. METHODS: Pregnant women with IBD receiving anti-TNF treatment were prospectively invited to participate in an electronic questionnaire carried out in 22 hospitals in Denmark, Australia, and New Zealand from 2011 to 2015. ..View full abstract
Supported by: The study was supported by unrestricted grants from the Health Research Fund of Central Denmark Region, Colitis-Crohn Denmark, and the A.P. Moeller Foundation of the Advancement of Medical Science. The external funders had no involvement in any aspect of the study or the writing of the report.